| DIRECT COMPETITOR COMPARISON | |
| ALNY | CYTR | MRK | VRX | Industry | | Market Cap: | 707.93M | 132.80M | 76.92B | 2.89B | 107.08M | | Employees: | 175 | 31 | 55,200 | 2,331 | 59 | | Qtrly Rev Growth (yoy): | -5.80% | 657.90% | 1.80% | 30.80% | 19.70% | | Revenue (ttm): | 98.31M | 10.83M | 23.37B | 772.95M | 13.84M | | Gross Margin (ttm): | -2.31% | 100.00% | 76.36% | 75.52% | 66.58% | | EBITDA (ttm): | -41.20M | -6.20M | 7.81B | 300.35M | -12.25M | | Oper Margins (ttm): | -48.68% | -63.11% | 26.63% | 28.93% | -158.08% | | Net Income (ttm): | -49.19M | -5.87M | 8.05B | -32.02M | N/A | | EPS (ttm): | -1.185 | -0.061 | 3.808 | -0.640 | -0.31 | | P/E (ttm): | N/A | N/A | 9.58 | N/A | 17.08 | | PEG (5 yr expected): | N/A | N/A | 2.44 | 0.77 | 1.15 | | P/S (ttm): | 7.20 | 12.27 | 3.29 | 3.74 | 9.82 |
|
| CYTR = CytRx Corporation | | MRK = Merck & Co. Inc. | | VRX = Valeant Pharmaceuticals International | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.21 | 0.00% | 56.92B | 12.69 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 54.09 | 0.00% | 15.64B | 18.10 | | Genzyme Corp. | GENZ | 54.87 | 0.00% | 14.56B | 31.28 | | Merck Serono S.A. | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.30 | 0.00% | 41.66B | 16.41 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 47.82 | 0.00% | 8.54B | 59.92 | | Teva Pharmaceutical Industries Limited | TEVA | 57.10 | 0.00% | 50.31B | 52.24 | | Sandoz International GmbH | Private - View Profile |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Watson Pharmaceuticals Inc. | WPI | 38.10 | 0.00% | 4.04B | 19.64 | | King Pharmaceuticals Inc. | KG | 11.44 | 0.00% | 2.84B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.68 | 0.00% | 5.40B | 108.47 | | Pfizer Inc. | PFE | 17.88 | 0.00% | 144.28B | 14.85 | | Johnson & Johnson | JNJ | 62.76 | 0.00% | 173.16B | 14.27 | | GlaxoSmithKline plc | GSK | 38.47 | 0.00% | 97.52B | 12.91 | | Sanofi-Aventis | SNY | 36.29 | 0.00% | 94.76B | N/A | | Novartis AG | NVS | 53.58 | 0.00% | 121.69B | 16.04 | | RHHBY.PK | 41.50 | 0.00% | N/A | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | AstraZeneca plc | AZN | 44.11 | 0.00% | 64.00B | 8.50 | | Abbott Laboratories | ABT | 53.35 | 0.00% | 82.52B | 14.44 | | Bristol-Myers Squibb Company | BMY | 24.25 | 0.00% | 48.04B | 4.51 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | MRK | | [$$] Investors Seek More Disclosure on Political Spending
Tue 6:26pm -
at The Wall Street Journal Online | | • | MRK | | [$$] Caterpillar Tops the Dow
Tue 3:16pm -
at RealMoney by TheStreet.com | | • | MRK | | What Bipartisan Health-Care Reform Means for Investors
Tue 1:56pm -
at Motley Fool | | • | MRK | | AstraZeneca Goes to the Well One Last Time
Tue 12:50pm -
at Minyanville.com | | • | MRK | | Don't Invest Another Penny
Tue 12:41pm -
at Motley Fool | | • | VRX | | Valeant Pharmaceuticals to Announce 2009 Fourth Quarter and Year Results on February 22, 2010
Mon, Feb 8 -
PR Newswire | | • | VRX | | Coverage initiated on Valeant Pharmaceuticals by Jefferies & Co
Fri, Feb 5 -
Briefing.com | | • | CYTR | | CytRx to Present at the 12th Annual BIO CEO & Investor Conference
Mon, Feb 1 -
Business Wire | | • | CYTR | | Biotech Bulls Becoming Restless
Sun, Jan 24 -
at Seeking Alpha | | • | CYTR | | CytRx Announces 2010 Clinical and Development Milestones
Thu, Jan 21 -
Business Wire | | • | VRX | | 3 Stocks Ready to Roar
Tue, Jan 19 -
at Motley Fool | | • | CYTR | | RXi Pharmaceuticals Talks Partnerships
Sat, Jan 16 -
at Seeking Alpha | | • | CYTR | | CytRx to Conduct Phase 2 Clinical Trial with Bafetinib in B-cell Chronic Lymphocytic Leukemia
Wed, Jan 13 -
Business Wire | | • | VRX | | VALEANT PHARMACEUTICALS INTERNATIONAL Files SEC form 8-K, Change in Directors or Principal Officers
Mon, Jan 11 -
EDGAR Online | | • | VRX | | Valeant Pharmaceuticals to Hold Conference Call to Announce 2010 Financial Guidance scheduled for 9:00 am ET today
Fri, Jan 8 -
CCBN | | • | CYTR | | Coverage initiated on CytRx by Roth Capital
Fri, Jan 8 -
Briefing.com | | • | CYTR | | CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
Thu, Jan 7 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.52% Nasdaq 0.00%
Competitors
